Abstract

BackgroundThe World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated malaria. Sudan revised its malaria treatment policy accordingly in 2004. However, eight years after ACTs were introduced in Sudan the patterns of ACT prescribing practices among health care providers remain unclear. We systematically analyzed use of ACTs in a large number of primary health facilities and we discuss the public health implications of our findings.MethodsThis cross-sectional study was based on WHO’s guidance for investigating drug use in health facilities. Data were collected from 40 randomly selected primary health centers in five localities in Gezira State, Sudan. The primary outcome of the study was the proportion of patients who were adequately managed according to Sudan’s recommended malaria treatment guidelines. Twelve drug-use indicators were used to assess key ACT prescribing practices.ResultsOne thousand and two hundred patients diagnosed with uncomplicated malaria were recruited into the study. ACT was prescribed for 88.6%patients and artemether injections were (incorrectly) prescribed in 9.5% of cases. Only 40.9% of patients in the study were correctly diagnosed and 26.9% were adequately managed according to the nationally recommended treatment guidelines. Incorrect prescribing activities included failure to use generic medicine names (88.2%), incorrect dosage (27.7%), and unexplained antibiotic co-prescription (24.2%). Dispensing practices were also poor, with labeling practices inadequate (97.1%) and insufficient information given to patients about their prescribed treatment (50.5%).ConclusionIrrational malaria treatment practices are common in Sudan. This has important public health implications since failure to adhere to nationally recommended guidelines could play a role in the future development of drug resistance. As such, identifying ways to improve the anti-malarial prescribing practices of heath workers in Sudan may be a priority.

Highlights

  • The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated malaria

  • Irrational malaria treatment practices are common in Sudan

  • This has important public health implications since failure to adhere to nationally recommended guidelines could play a role in the future development of drug resistance

Read more

Summary

Introduction

The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated malaria. The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as firstline treatment for uncomplicated malaria [1,2]. Artemisinin resistance has been observed in four Southeast Asian countries (Cambodia, Myanmar, Thailand, and Viet Nam) [4,5,6]. This has been attributed to factors including irrational prescribing practices, poor patient compliance with prescribed regimens, improper use of artemisinin monotherapies, and inadequate access to quality assured forms of the drug [7,8,9]. While resistance to ACTs has not yet been observed, concern exists that poor treatment practices may promote ACT resistance in the future, a situation similar to the global spread of chloroquine resistance that has occured [11]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call